BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 18408341)

  • 1. [Pharmacological and clinical profiles of long-lasting erythropoiesis-stimulating agent (darbepoetin alfa; NESP].
    Nagano N
    Nihon Yakurigaku Zasshi; 2008 Apr; 131(4):291-9. PubMed ID: 18408341
    [No Abstract]   [Full Text] [Related]  

  • 2. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.
    Wilhelm-Leen ER; Winkelmayer WC
    Am J Kidney Dis; 2015 Jul; 66(1):69-74. PubMed ID: 25636816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing anemia in patients with chronic kidney disease or cancer: development and role of darbepoetin alfa.
    Scott SD
    Pharmacotherapy; 2002 Sep; 22(9 Pt 2):129S-132S. PubMed ID: 12222582
    [No Abstract]   [Full Text] [Related]  

  • 4. Change in darbepoetin alfa administration schedule affects erythropoiesis-stimulating agent resistance in patients with chronic kidney disease receiving hemodialysis.
    Molina M; Navarro MJ; de Gracia C; Alvarez G; de Alarcon R; Garcia MA
    Ren Fail; 2008; 30(8):778-83. PubMed ID: 18791951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis.
    Li WY; Chu TS; Huang JW; Wu MS; Wu KD
    J Formos Med Assoc; 2008 Nov; 107(11):843-50. PubMed ID: 18971153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoietin in kidney disease and type 2 diabetes.
    Thum T; Kalantar-Zadeh K; Anker SD
    N Engl J Med; 2011 Jan; 364(4):384-5; author reply 385-6. PubMed ID: 21268744
    [No Abstract]   [Full Text] [Related]  

  • 7. Erythropoietin in kidney disease and type 2 diabetes.
    Locatelli F; Del Vecchio L; Casartelli D
    N Engl J Med; 2011 Jan; 364(4):384; author reply 385-6. PubMed ID: 21268745
    [No Abstract]   [Full Text] [Related]  

  • 8. Anemia in chronic kidney disease: causes, diagnosis, treatment.
    Nurko S
    Cleve Clin J Med; 2006 Mar; 73(3):289-97. PubMed ID: 16548452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin in kidney disease and type 2 diabetes.
    Schnuelle P; Benck U; Krämer BK
    N Engl J Med; 2011 Jan; 364(4):384; author reply 385-6. PubMed ID: 21268746
    [No Abstract]   [Full Text] [Related]  

  • 10. Darbepoetin alfa for treatment of anaemia in a case of chronic renal failure during pregnancy--case report.
    Ghosh A; Ayers KJ
    Clin Exp Obstet Gynecol; 2007; 34(3):193-4. PubMed ID: 17937101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical guidelines for the use of NESP in treating renal anaemia.
    Aljama P; Bommer J; Canaud B; Carrera F; Eckardt KU; Hörl WH; Krediet RT; Locatelli F; Macdougall IC; Wikström B;
    Nephrol Dial Transplant; 2001; 16 Suppl 3():22-8. PubMed ID: 11402087
    [No Abstract]   [Full Text] [Related]  

  • 12. Darbepoetin Alfa Versus Erythropoietin Alfa for Treatment of Renal Anemia in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage: A Randomized Non-inferiority Trial.
    Mehta KS; Sinha SD; Vamsi B; Reddy B; Naidu NR; Thakur PA; Sreenivasa C; Reddy VPR; Pandey R; Durugkar S
    J Assoc Physicians India; 2019 Jan; 67(1):62-66. PubMed ID: 30935177
    [No Abstract]   [Full Text] [Related]  

  • 13. Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia.
    Bohlius J; Engert A; Schwarzer G
    JAMA; 2008 Dec; 300(24):2854-5; author reply 2855-7. PubMed ID: 19109112
    [No Abstract]   [Full Text] [Related]  

  • 14. Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease.
    Warady BA; Arar MY; Lerner G; Nakanishi AM; Stehman-Breen C
    Pediatr Nephrol; 2006 Aug; 21(8):1144-52. PubMed ID: 16724235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
    Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
    J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
    Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA
    Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved haemoglobin concentrations with IV darbepoetin alfa--case studies of haemodialysis patients.
    Thiele A; Wittner M
    Curr Med Res Opin; 2002; 18(7):440-4. PubMed ID: 12487509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current issues in erythropoietin therapy of renal anemia].
    Zakar G
    Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anemia treatment in patients with chronic kidney disease.
    Drüeke TB
    N Engl J Med; 2013 Jan; 368(4):387-9. PubMed ID: 23343068
    [No Abstract]   [Full Text] [Related]  

  • 20. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials.
    Mann J; Kessler M; Villa G; Martinez-Castelao A; Feldt-Rasmussen B; Cruz J; Hörl WH; Mattin C; Praml C; Wilkie M
    Clin Nephrol; 2007 Mar; 67(3):140-8. PubMed ID: 17390738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.